Venatorx and Melinta Provide Update on Status of U.S. New Drug Application for Cefepime-Taniborbactam

Malvern, PA, and Parsippany, NJ– February 23, 2024– Venatorx Pharmaceuticals (Venatorx) and Melinta Therapeutics (Melinta) announced today that the U.S. Food and Drug Administration (FDA) issued a Complete Response Letter (CRL)...

https://www.drugs.com/nda/cefepime_taniborbactam_240223.html

Source: Drugs.com - New Drug Applications - February 23, 2024 Category: Drugs & Pharmacology Source Type: news

More News: Drugs & Pharmacology | Food and Drug Administration (FDA) | New Drug Applications